Dr. Shah on Potential for Daratumumab Maintenance in Multiple Myeloma

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the potential for daratumumab (Darzalex) maintenance therapy in multiple myeloma.

Lenalidomide (Revlimid) is currently the standard maintenance therapy in the United States. However, in the phase III AURIGA trial, investigators will evaluate the efficacy of adding daratumumab to lenalidomide in the maintenance setting.

The trial, which is set to open at UCSF, will randomize patients who are in complete response or very good partial response, but are minimal residual disease (MRD) positive by next-generation sequencing, to receive either maintenance daratumumab and lenalidomide or lenalidomide alone after transplant. The MRD negativity end point is 12 months, which will help investigators answer questions more quickly rather than waiting for progression-free survival results, concludes Shah.